<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026454</url>
  </required_header>
  <id_info>
    <org_study_id>37162-A</org_study_id>
    <nct_id>NCT01026454</nct_id>
  </id_info>
  <brief_title>Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons</brief_title>
  <acronym>ACV-VAL</acronym>
  <official_title>A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treating HSV-2 with either valacyclovir or
      acyclovir is more effective in suppressing HIV-1 virus levels in people co-infected with
      HIV-1 and HSV-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sexual transmission is responsible for the vast majority of HIV-1 infections among adults
      worldwide. In sub-Saharan Africa, the region hardest hit by the HIV-1 epidemic, HSV-2
      prevalences of 30-50% have been seen in the general population with prevalence up to 90% in
      infected with HIV-1. HSV-2 is common in those with, or at risk for, HIV-1 infection, and
      HSV-2 reactivation increases HIV-1 acquisition and infectiousness. Recent studies have shown
      that suppression of HSV-2 has a sustained effect on lowering HIV-1 levels in blood plasma.
      New data have raised the question whether higher doses of HSV-2 suppressive therapy might be
      more effective at suppressing HIV-1 levels. Acyclovir and valacyclovir, chosen for use in
      this study, are safe and effective treatments for decreasing the frequency of HSV-2
      reactivation and shedding. The standard dose of acyclovir is 400 mg twice a day.
      Valacyclovir, a drug that converts to acyclovir after absorption, delivers higher
      concentrations of acyclovir. 1.5 grams of valacyclovir, will be used to provide a higher dose
      of acyclovir, and will be compared with the standard dose of 400 mg twice a day of acyclovir.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir.</measure>
    <time_frame>Weekly for 12 weeks per intervention</time_frame>
    <description>Mean level of HIV-1 RNA in plasma of participants while on 400 mg twice daily of acyclovir versus while on 1.5 g twice daily of valacyclovir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Valacyclovir 1.5 Gram Orally Twice Daily in HIV-1 Seropositive Persons.</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HSV Infection</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>acyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>acyclovir 400 mg orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>valacyclovir 1.5 g orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
    <description>acyclovir 400 mg orally, twice daily for 12 weeks</description>
    <arm_group_label>acyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>valacyclovir 1.5 g orally, twice daily, for 12 weeks</description>
    <arm_group_label>valacyclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 seropositive

          -  Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy
             during the study period

          -  CD4 cell count &gt;250 cell/ÂµL

          -  Not otherwise eligible for antiretroviral therapy according to Uganda national
             guidelines

          -  Detectable HIV-1 plasma viral load

          -  HSV-2 seropositive

          -  Not intending to move out of the area for the duration of study participation.

          -  Able to participate in the study at the Partners in Prevention site in Thika, Kenya

        Exclusion Criteria:

          -  Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir.

          -  Planned use of acyclovir, valacyclovir, or famciclovir

          -  Use of ganciclovir, foscarnet, or cidofovir

          -  Known medical history of seizures

          -  Serum creatinine &gt;1.5 mg/dL

          -  AST or ALT &gt;3 times upper limit of normal

          -  Hematocrit &lt;30 %

          -  Absolute neutrophil count &lt;1000

          -  Platelet count &lt;75,000

          -  History of thrombotic microangiopathy

          -  Any other condition which, in the opinion of the principal investigator, may
             compromise the ability to follow study procedures and complete the study

          -  Participation in another HIV therapeutics trial

          -  For women, pregnancy as confirmed by a urine pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Celum, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thika Partners in Prevention</name>
      <address>
        <city>Thika</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Brown EL, Wald A, Hughes JP, Morrow RA, Krantz E, Mayer K, Buchbinder S, Koblin B, Celum C. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol. 2006 Oct 15;164(8):733-41. Epub 2006 Aug 8.</citation>
    <PMID>16896053</PMID>
  </reference>
  <reference>
    <citation>Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006 Jan 2;20(1):73-83. Review.</citation>
    <PMID>16327322</PMID>
  </reference>
  <reference>
    <citation>Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 2002 Dec 15;186(12):1718-25. Epub 2002 Nov 22.</citation>
    <PMID>12447756</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>November 15, 2013</results_first_submitted>
  <results_first_submitted_qc>January 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2014</results_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Connie Celum</investigator_full_name>
    <investigator_title>US Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HSV-2/HIV-1 dually-infected participants were recruited between March and November 2010 from Thika, Kenya.</recruitment_details>
      <pre_assignment_details>66 participants screened; 34 excluded (33 did not meet inclusion criteria, 1 declined study participation); 32 enrolled</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyclovir Then Valacyclovir</title>
          <description>Acyclovir 400 mg orally twice daily (12 weeks), Washout (2 weeks), Valacyclovir 1.5 g orally twice daily (12 weeks)</description>
        </group>
        <group group_id="P2">
          <title>Valacyclovir Then Acyclovir</title>
          <description>Valacyclovir 1.5 g orally twice daily (12 weeks), Washout (2 weeks), Acyclovir 400 mg orally twice daily (12 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyclovir Then Valacyclovir</title>
          <description>acyclovir 400 mg orally twice daily for 12 weeks, 2 week washout, then valacyclovir 1.5 g orally twice daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Valacyclovir Then Acyclovir</title>
          <description>valacyclovir 1.5 g orally twice daily for 12 weeks, 2 week washout, then acyclovir 400 mg orally twice daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA Level at Enrollment</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.05" spread="0.72"/>
                    <measurement group_id="B2" value="4.08" spread="0.85"/>
                    <measurement group_id="B3" value="4.07" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir.</title>
        <description>Mean level of HIV-1 RNA in plasma of participants while on 400 mg twice daily of acyclovir versus while on 1.5 g twice daily of valacyclovir.</description>
        <time_frame>Weekly for 12 weeks per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir</title>
            <description>acyclovir 400 mg twice daily 400 mg either in first intervention period or second</description>
          </group>
          <group group_id="O2">
            <title>Valacyclovir</title>
            <description>valacyclovir 1.5 g twice daily either in first intervention period or second</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir.</title>
          <description>Mean level of HIV-1 RNA in plasma of participants while on 400 mg twice daily of acyclovir versus while on 1.5 g twice daily of valacyclovir.</description>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" lower_limit="3.26" upper_limit="3.85"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.65" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Valacyclovir 1.5 Gram Orally Twice Daily in HIV-1 Seropositive Persons.</title>
        <time_frame>28 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acyclovir</title>
          <description>acyclovir 400 mg twice daily 400 mg either in first intervention period or second</description>
        </group>
        <group group_id="E2">
          <title>Valacyclovir</title>
          <description>valacyclovir 1.5 g twice daily either in first intervention period or second</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Connie Celum, MD, MPH</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-520-3800</phone>
      <email>ccelum@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

